Dermatology

RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.

RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.

RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.

RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.

RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.

RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.

RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.

Preview of 10 new studies on managing atopic dermatitis, including biologics, treatment barriers, and innovative care strategies for clinicians.

The AI model showed high accuracy in detecting body parts and eczema areas, with strong correlation to physician assessments, researchers reported.

Results showed that a nanoencapsulated CBD cream reduced UV-A–induced nuclear and mitochondrial DNA damage linked to photoaging in human skin.

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Your daily dose of the clinical news you may have missed.

New data also demonstrated mixed sex disparities in elderly atopic dermatitis prevalence.

Dupilumab (Dupixent) is the first new targeted therapy for CSU in over a decade.

New data highlight the potential of dupilumab, remibrutinib, and barzolvolimab to expand treatment options for patients with CSU unresponsive to current therapies.

Your daily dose of the clinical news you may have missed.

The investigational botanical zabalafin hydrogel has shown antipruritic, antibacterial, and anti-inflammatory properties, addressing the multifactorial nature of AD.

Black children were 2.4 to 4.1 times more likely to experience early-onset and persistent disease than White peers and much more likely to require urgent care for their AD.

William Lewis, MD, discussed the importance of photo-documentation, referral indicators, efficacy of various treatments, and other topics.

Highlights from AAD 2025: Experts share updates on systemic therapy for atopic dermatitis, pediatric rashes, and contact dermatitis for PCPs.

Dupilumab significantly improved measures of severe AD, including EASI and IGA, as well as pruritis in pediatric populations aged 6 months to 18 years vs placebo.

The April issue covers atopic dermatitis, highlighting primary care’s role in early diagnosis, key updates from recent conferences, and more.

AAD 2025: Raj Chovatiya, MD, PhD, MSCI, well-known physician scientist, says underrepresentation in clinical trials of those with skin of color precludes an evidence-based answer.

Raj Chovatiya, MD, PhD, MSCI, discusses the complex and widely variable influences that affect the manifestations and burden of atopic dermatitis across populations.